ArticleNPJ science of food2026
Lactiplantibacillus plantarum SLpl116 attenuates OVA-induced food allergy with ecological restoration of the gut microbiota and immune rebalancing.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gut dysbiosis is increasingly recognized as a key contributor to food allergy, yet probiotic strains capable of restoring allergic microbiota and rebalancing host immunity remain limited. Here, we identified Lactiplantibacillus plantarum SLpl116 through a multi-criteria screening pipeline integrating anti-allergic activity, safety, and processing stability, and evaluated its efficacy in a prophylactic ovalbumin (OVA)-induced murine food allergy model. SLpl116 significantly attenuated allergic symptoms, including diarrhea and hypothermia, and suppressed serum IgE, IgG1, OVA-specific immunoglobulins, and mucosal mast cell protease-1. It was also associated with suppression of Th2-related responses and enhancement of systemic Th1-associated signaling, indicating restoration of Th1/Th2 immune balance. Microbiome analysis showed that SLpl116 was associated with ecological restoration of the dysbiotic gut community, including suppression of allergy-associated taxa such as Alistipes finegoldii and Bacteroides and enrichment of beneficial commensals, particularly Lachnospiraceae. Correlation analysis supported an association between microbial reconfiguration and immune rebalancing, while PICRUSt2-based functional prediction suggested enriched butyrate-associated metabolic potential in the effective strain groups. Comparative genome-informed analysis further indicated that SLpl116 possessed distinctive phenotype-linked features, providing a plausible molecular rationale for its favorable phenotype. Together, these findings identify SLpl116 as a promising strain-level probiotic candidate associated with direct immune rebalancing and microbiome-associated ecological restoration.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.